Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
September 02 2021 - 07:00AM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage
cell therapy company developing therapies with the potential to
transform the standard of care in solid organ transplantation,
certain severe autoimmune diseases, and certain severe
non-malignant blood, immune and metabolic disorders, today
announced that members of its senior management team will
participate at the following investor conferences:
Morgan Stanley Virtual 19th Annual Global Healthcare
ConferenceFireside Chat Date: Monday, September 13,
2021Time: 5:00 PM ET
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases
& Genetic Medicines 1x1 EventDate: September 22-23,
2021
A live webcast of the fireside chat at the Morgan Stanley
Virtual 19th Annual Global Healthcare Conference will be available
on the investors section of the Talaris website at
www.talaristx.com. After the live webcast, the event will remain
archived on the Talaris website for 90 days.
About Talaris TherapeuticsTalaris Therapeutics,
Inc. is a late-clinical stage biopharmaceutical company developing
investigational, one-time, allogeneic cell therapies with the
potential to transform the standard of care in solid organ
transplantation, certain severe autoimmune diseases, and certain
severe non-malignant blood, immune and metabolic disorders. Talaris
maintains corporate offices in Boston, MA, and its cell processing
facility in Louisville, KY. For additional information, visit
talaristx.com, and follow us on Twitter, LinkedIn and Facebook.
Media ContactLisa RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com(617)
903-8783
Investor ContactChris BrinzeyWestwicke, an ICR
Companychris.brinzey@westwicke.com (339)
970-2843
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Mar 2023 to Mar 2024